Methane

Methane

SCHEMBL4457656

C.Oc1ccnc2ccccc12

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.54
LOXL2 Q9Y4K0 1/20 0.50
MAPT P10636 4/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.47
CASP3 P42574 1/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
HTR1A P08908 2/20 0.47
ADRA1D P25100 2/20 0.47
ADRA1A P35348 2/20 0.47
ADRA1B P35368 2/20 0.47
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 2/20 0.46
TP53 P04637 2/20 0.46
RAB9A P51151 2/20 0.46
PTK2B Q14289 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL128549 0.98 NCF1 (0.56) NCF1LOXL2MAPTALDH1A1HPGD
Water SCHEMBL11636960 0.95 NCF1 (0.54) NCF1LOXL2MAPTALDH1A1HPGD
SCHEMBL28195065 0.95 NCF1 (0.54) NCF1LOXL2MAPTALDH1A1HPGD
Hydrochloric Acid SCHEMBL8722622 0.95 NCF1 (0.54) NCF1LOXL2MAPTALDH1A1HPGD
SCHEMBL31139499 0.95 NCF1 (0.54) NCF1LOXL2MAPTALDH1A1HPGD
SCHEMBL28398977 0.95 NCF1 (0.54) NCF1LOXL2MAPTALDH1A1HPGD
Ammonia Solution, Strong SCHEMBL28083889 0.95 NCF1 (0.54) NCF1LOXL2MAPTALDH1A1HPGD
Ethane SCHEMBL6176957 0.93 NCF1 (0.52) NCF1LOXL2MAPTALDH1A1HPGD
Methyl Alcohol SCHEMBL8862947 0.93 NCF1 (0.52) NCF1LOXL2MAPTALDH1A1HPGD
Formaldehyde SCHEMBL27745422 0.91 NCF1 (0.50) NCF1LOXL2MAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119432383-A High-selectivity etching solution for radio frequency chip material 湖北兴福电子材料股份有限公司 2025-02-14 CN disclosed
WO-2012068560-A3 4-QUINOLINEMETHANOLS AS ANTI-MALARIAL AGENTS JENRIN DISCOVERY (US) 2013-08-15 WO disclosed
CN-101474152-A Mefloquine fat emulsion composition and method for preparing the same UNIV NORTHWESTERN POLYTECHNIC (CN) 2009-07-08 CN disclosed
US-20090124658-A1 Treatments for Viral Infections KELLER ROBERT H 2009-05-14 US disclosed
US-7479498-B2 Treatments for viral infections PHOENIX BIOSCIENCES, INC. (US) 2009-01-20 US disclosed
CN-101300249-A Aminoquinoline and aminoquinazoline kinase modulators JANSSEN PHARMACEUTICA NV (BE) 2008-11-05 CN disclosed
CN-101291922-A Alkylquinoline and alkylquinazoline kinase modulators JANSSEN PHARMACEUTICA NV (BE) 2008-10-22 CN disclosed
EP-1450803-A4 NEW USES FOR ANTI-MALARIAL THERAPEUTIC AGENTS CHAROUS LAUREN (US) 2008-09-03 EP disclosed
CN-101243065-A Intermediates for the synthesis of alkylquinoline and alkylquinazoline kinase modulators and related synthetic methods JANSSEN PHARMACEUTICA NV (BE) 2008-08-13 CN disclosed
CN-1994466-A Use of composition for treatment of viral infections MP 1 INC (US) 2007-07-11 CN disclosed
US-6734192-B1 ADMINISTERING QUERCETIN OR DERIVATIVES THEREOF, WITH THE CHANNEL BLOCKER AND QUINOLINE FOR TREATMENT OF HIV INFECTION MP-1 INC. 2004-05-11 US disclosed
US-20030224008-A1 Novel uses for anti-malarial therapeutic agents APT PHARMACEUTICALS, LLC (US) 2003-12-04 US disclosed
US-6572858-B1 Treating inflammatory conditions including pulmonary diseases states, such as asthma using antimalarial agents via non-systemic administration; hydroxychloroquine via inhalation APT PHARMACEUTICALS, LLC 2003-06-03 US disclosed
WO-2003039546-A1 NEW USES FOR ANTI-MALARIAL THERAPEUTIC AGENTS CHAROUS LAUREN (US) 2003-05-15 WO disclosed
WO-2003039488-A2 A METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE CHAROUS LAUREN (US) 2003-05-15 WO disclosed
CN-1399558-A Treatment of viral infections IMMUNE BALANCE TECHNOLOGIES CO (US) 2003-02-26 CN disclosed
EP-1210116-A2 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF VIRAL INFECTIONS CONTAINING A CALCIUM CHANNEL BLOCKER AND A QUINOLINE Immune Balance Technologies Limited Company (US) 2002-06-05 EP disclosed
EP-1175216-A2 ANTIMALARIAN AGENTS FOR THE TREATMENT OF ASTHMA APT Pharmaceutical, L.L.C. (US) 2002-01-30 EP disclosed
WO-2001013907-A2 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF VIRAL INFECTIONS CONTAINING A CALCIUM CHANNEL BLOCKER AND A QUINOLINE IMMUNE BALANCE TECHNOLOGIES LIMITED COMPANY (US) 2001-03-01 WO disclosed
WO-2000066107-A2 ANTIMALARIAN AGENTS FOR THE TREATMENT OF ASTHMA APT PHARMACEUTICALS, L.L.C. (US) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030224008-A1 Novel uses for anti-malarial therapeutic agents IL5, CCL11, TSLP NCF1 997/4885LOXL2 1795/4885MAPT 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.